Reports that a potential new trivalent vaccine against herpes simplex virus-2 (HSV-2) infection developed at the Perelman School of Medicine, University of Pennsylvania, has provided protection against herpes infection in early stage studies come at a time when other strategies are also starting to show promise against this public health problem.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?